NeoGenomics (NEO) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
NeoGenomics Reports Revenue of $87 Million in the Second Quarter amid COVID-19 Pandemic
July 28, 2020 7:02 AM EDTSecond-Quarter 2020 Results and Highlights:
Consolidated revenue decreased 14% to $87 millionClinical Services revenue decreased 17% to $74 millionPharma Services revenue increased 3% to $13 millionPharma Services backlog increased 63% to $173 millionFinancial position strengthened with $322 million net convertible note and equity offeringsTest menu expanded with suite of solid tumor liquid biopsy testsStrategic collaboration and minority investment in Inivata establishedHigh-capacity COVID-19 testing lab operationalizedFORT MYERS, FL / ACCESSWIRE / July 28, 2020 / NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of... More
